<DOC>
	<DOC>NCT00857896</DOC>
	<brief_summary>The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.</brief_summary>
	<brief_title>Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>A total body weight &gt;25 kg (55 lbs). Symptoms of urinary frequency (average â‰¥8 daily bathroom visits to urinate) and urgency to urinate, with or without urgency incontinence, for at least 6 months prior to enrolment, OR Stable neurological disease and urodynamically confirmed detrusor overactivity, who may require intermittent catheterization for management of urinary drainage. Treatment with an investigational drug within 4 weeks or 5 halflives, whichever is longer, before first study dose Ongoing use of potent CYP3A4 inhibitors or inducers or CYP2D6 inhibitors Ongoing use of another drug for treating overactive bladder Uncontrolled narrow angle glaucoma, urinary or gastric retention</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Study of fesoterodine in pediatric overactive bladder patients</keyword>
</DOC>